HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

This article was originally published in The Rose Sheet

Executive Summary

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

You may also be interested in...



NAD: Anti-Aging Claims ‘Muted A Bit,’ But Vigilance Remains High

Anti-aging claims in the cosmetics sector show improved compliance with advertising standards overall, but the National Advertising Division remains on the lookout for potential overstatements, particularly as personal-care companies are less inclined to challenge each other than players in other industries.

FTC Updates Policy For Unmasking 'Native Advertising'

FTC publishes an enforcement policy statement addressing a rise in native advertising and deceptively formatted ads. The statement explains how the commission will apply its current enforcement standards to target deceptive content, including promotions disguised as news stories in violation of its policies.

FTC Updates Endorsement Guide Resource: 'What People Are Asking'

Agency's updated FAQ web page tackles questions stakeholders have been asking in recent years about its Endorsement Guide, including the appropriate way to provide disclosures on social-media platforms and the responsibilities of companies using large networks of bloggers and other influencers to promote products.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel